Literature DB >> 16612467

Estrogen receptor 1 gene polymorphisms and coronary artery disease in the Brazilian population.

S Almeida1, M H Hutz.   

Abstract

We examined the association of three established single nucleotide polymorphisms, IVS1-397T>C, IVS1-351A>G, and +261G>C, in the ESR1 gene with the prevalence and severity of coronary atherosclerosis in a southern Brazilian population of European ancestry. Three hundred and forty-one subjects (127 women and 214 men) with coronary artery disease (CAD) were classified as having significant disease (CAD+ patient group) when they showed 60% or more luminal stenosis in at least one coronary artery or major branch segment at angiography; patients with 10% or less luminal stenosis were considered to have minimal CAD (CAD- patient group). The control sample consisted of 142 subjects (79 women and 63 men) without significant disease, in whom coronary angiography to rule out the presence of asymptomatic CAD was not performed. The polymorphisms were investigated by polymerase chain reaction followed by restriction analyses. In the male sample, the +261G>C*C allele was more frequent in CAD+ than CAD- subjects (8 versus 1%, P = 0.024). Homozygosity for the C allele of the IVS1-397T>C polymorphism was also significantly associated with increased CAD severity (OR: 2.99; 95% CI = 1.35-6.63; P = 0.007). In agreement with previous findings, these results suggest that the IVS1-397T>C*C allele was associated with CAD severity independent of gender, whereas the association of the +261G>C variant with CAD was observed in males only. The relation between ESR1 variation and CAD may influence clinical decisions such as the use of hormone therapy, and additionally will be helpful to identify the genetic susceptibility determinants of cardiovascular disease development.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16612467     DOI: 10.1590/s0100-879x2006000400004

Source DB:  PubMed          Journal:  Braz J Med Biol Res        ISSN: 0100-879X            Impact factor:   2.590


  6 in total

1.  GAS5/METTL14/ESR1 genetic variants are related to the susceptibility of coronary heart disease.

Authors:  Yuxiao Sun; Zhaoyun Cheng; Mingxia Cui; Yan Chen; Ruigang Xie; Guoqing Lu; Chuanyu Gao
Journal:  Funct Integr Genomics       Date:  2022-03-02       Impact factor: 3.410

2.  Polymorphisms and haplotypes of the estrogen receptor-beta gene (ESR2) and cardiovascular disease in men and women.

Authors:  Kathryn M Rexrode; Paul M Ridker; Hillary H Hegener; Julie E Buring; Joann E Manson; Robert Y L Zee
Journal:  Clin Chem       Date:  2007-08-16       Impact factor: 8.327

Review 3.  Estrogen receptor α gene PvuII polymorphism and coronary artery disease: a meta-analysis of 21 studies.

Authors:  Jie Ding; Hui Xu; Xiang Yin; Fu-rong Zhang; Xiao-ping Pan; Yi-an Gu; Jun-zhu Chen; Xiao-gang Guo
Journal:  J Zhejiang Univ Sci B       Date:  2014-03       Impact factor: 3.066

4.  Association of the polymorphisms of the genes APOC3 (rs2854116), ESR2 (rs3020450), HFE (rs1799945), MMP1 (rs1799750) and PPARG (rs1801282) with lipodystrophy in people living with HIV on antiretroviral therapy: a systematic review.

Authors:  Andreia Soares da Silva; Tatiana Lins Carvalho; Kleyton Palmeira do Ó; Débora Nascimento da Nóbrega; Roberta Dos Santos Souza; Victor Fernando da Silva Lima; Isabela Cristina Cordeiro Farias; Taciana Furtado de Mendonça Belmont; Maria do Socorro de Mendonça Cavalcanti; Demócrito de Barros Miranda-Filho
Journal:  Mol Biol Rep       Date:  2020-04-22       Impact factor: 2.316

5.  Integration of partial least squares and Monte Carlo gene expression analysis in coronary artery disease.

Authors:  Huan Zhang; Tao Li; Guanji Wu; Feng Ma
Journal:  Exp Ther Med       Date:  2014-03-07       Impact factor: 2.447

6.  Endothelial function and insulin resistance in early postmenopausal women with cardiovascular risk factors: importance of ESR1 and NOS3 polymorphisms.

Authors:  Ruth Clapauch; André Felipe Mourão; Anete S Mecenas; Priscila A Maranhão; Ana Rossini; Eliete Bouskela
Journal:  PLoS One       Date:  2014-07-31       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.